Tradestie Institutional Equity Comparison Engine
EW vs DXCM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DXCM Overall Edge
DXCM Captures Institutional Edge (4โ0 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DexCom, Inc. (DXCM) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, EW trades at 31.6x Forward P/E with 28.8% operating margin (+10.5% YoY revenue) versus DXCM at 26.6x Forward P/E and 24.0% operating margin (+11.2% YoY). In options structure, EW sits in UNCLASSIFIED (34th %ile IV; Dealer Gamma Walls on Pro) against DXCM sits in CONSOLIDATION (9th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
DXCM
EW 31.6x vs DXCM 26.6x Fwd P/E
Growth & Margin Winner
DXCM
Op Margin 28.8% vs 24.0% ยท YoY +10.5% vs +11.2%
Momentum & Technical Winner
DXCM
1Y +23.9% vs +36.6% ยท 52W Pos 96% vs 69%
Options & Structure Winner
DXCM
UNCLASSIFIED (34th %ile IV) vs CONSOLIDATION (9th %ile IV)
EW
NYSE
Edwards Lifesciences Corp
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$106.66
-0.46% 1D
Market Cap
$60.8B
1M Return
+23.16%
1Y Return
+23.86%
Forward P/E
31.6x
Unified AI Score
31.5 / 100
SELL
Tech 50.0
Fund 29.0
Flow 51.0
Mom 44.0
DXCM
NASDAQ
DexCom, Inc.
Surgical & Medical Instruments & Apparatus
$81.58
-2.11% 1D
Market Cap
$30.4B
1M Return
-5.19%
1Y Return
+36.6%
Forward P/E
26.6x
Unified AI Score
53.8 / 100
HOLD
Tech 74.0
Fund 67.0
Flow 68.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
EW +23.86%
DXCM +36.6%
Spread: +12.74 pp (DXCM Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | EW Revenue | DXCM Revenue | EW Op. Margin | DXCM Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $3.72B | $1.03B | 20.1% | -18.1% | EW |
| FY2019 | $4.35B | $1.48B | 26.4% | 9.6% | EW |
| FY2020 | $4.39B | $1.93B | 20.5% | 15.5% | EW |
| FY2021 | $5.23B | $2.45B | 32.3% | 10.9% | EW |
| FY2022 | $4.46B | $2.91B | 33.6% | 13.4% | EW |
| FY2023 | $5.01B | $3.62B | 26.1% | 16.5% | EW |
| FY2024 | $5.44B | $4.03B | 25.3% | 14.9% | EW |
| FY2025 | $6.07B | $4.66B | 20.8% | 19.6% | EW |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EW | DXCM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $60.8B | $30.4B | Larger Scale | EW |
| Trailing P/E Ratio Valuation | 61.5x | 32.0x | Lower Multiple | DXCM |
| Forward P/E Ratio Valuation | 31.6x | 26.6x | Lower Multiple | DXCM |
| Revenue Growth (YoY) Growth | +10.5% | +11.2% | Higher Growth | DXCM |
| Operating Margin (TTM) Profitability | 28.8% | 24.0% | Higher Margin | EW |
| Net Profit Margin Profitability | 15.3% | 19.4% | Higher Margin | DXCM |
| Return on Equity (ROE) Capital Efficiency | 9.3% | 37.7% | Higher ROE | DXCM |
| 52-Week Range Position Momentum | 96% ($75โ$108) | 69% ($57โ$93) | Stronger Trend | EW |
| Beta / 30D Volatility Risk Regime | 0.44ฮฒ ยท 24% Vol | 0.61ฮฒ ยท 49% Vol | Lower Realized Risk | EW |
| Unified Institutional Score Composite Signal | 31.5 / 100 (SELL) | 53.8 / 100 (HOLD) | Higher Composite | DXCM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full EW vs DXCM Buy Guide
EW
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
34th %ile
IV Regime
Balanced (25thโ60th %ile)
DXCM
CONSOLIDATION
69d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
9th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither EW nor DXCM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.